REVIEW ARTICLE
Nonsteroidal Anti-Inflammatory drugs and cardiovascular risk
Patricia A. Howard, PharmD, FCCP, BCPS (AQ CV)*,* and
Patrice Delafontaine, MD, FACC, FESC, FAHA, FACP
* Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, Kansas, USA
Division of Cardiovascular Diseases, University of Kansas Medical Center, Kansas City, Kansas, USA
Manuscript received March 6, 2003;
revised manuscript received June 3, 2003,
accepted September 10, 2003.
* Reprint requests and correspondence: Dr. Patricia A. Howard, Department of Pharmacy Practice, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, Kansas 66160-7231, USA.
phoward{at}kumc.edu
Nonsteroidal anti-inflammatory drugs (NSAID) inhibit cyclooxygenase (COX) enzymes, which exist in at least two isoforms, COX-1 and COX-2. Aspirin and older agents in this class are nonselective inhibitors of both COX-1 and COX-2. Newer agents termed "coxibs" are selective inhibitors of COX-2. Among the NSAID, only aspirin has been proven to significantly reduce cardiovascular risk, primarily through inhibition of COX-1-mediated platelet aggregation. It has been suggested that other nonselective agents, especially naproxen, may provide some lesser degree of cardioprotection, but conclusive evidence is lacking. Conversely, there are concerns that the COX-2 inhibitors may increase cardiovascular risk. However, mechanisms for this potentially adverse cardiovascular effect are unknown, and it is becoming increasingly clear that our understanding of the role of COX-2 in cardiovascular function is incomplete. Some studies have demonstrated a potentially beneficial effect of COX-2 on cardiovascular function that could be negated by COX-2 inhibition, while other studies have reported improved endothelial function with COX-2 inhibitors. Additionally, the impact of combined therapy with aspirin and other COX inhibitors is not yet clear. This article will review the studies that have examined these issues.
|
Abbreviations and Acronyms
| | CHD | = coronary heart disease | | CLASS | = Celecoxib Long-term Arthritis Safety study | | COX | = cyclooxygenase | | MI | = myocardial infarction | | NANSAID | = nonaspirin nonsteroidal anti-inflammatory drugs | | NSAID | = nonsteroidal anti-inflammatory drugs | | VIGOR | = Vioxx Gastrointestinal Outcomes Research study |
|
This article has been cited by other articles:
|
|
|
|
 
J. C Waksman, A. Brody, and S. D Phillips
Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?
Ann. Pharmacother.,
July 1, 2007;
41(7):
1163 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Salinas, U. C. Rangasetty, B. F. Uretsky, and Y. Birnbaum
The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame
Journal of Cardiovascular Pharmacology and Therapeutics,
June 1, 2007;
12(2):
98 - 111.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. T. Chan, G. C. Curhan, E. B. Rimm, W. C. Willett, C. S. Fuchs, J. E. Manson, C. M. Albert, C. U. Chae, and K. M. Rexrode
Response to Letter Regarding Article, "Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events"
Circulation,
September 12, 2006;
114(11):
e496 - e496.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Lippi, M Franchini, G C Guidi, and W F Kean
Non-steroidal anti-inflammatory drugs in athletes * Commentary
Br. J. Sports Med.,
August 1, 2006;
40(8):
661 - 663.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Chan, J. E. Manson, C. M. Albert, C. U. Chae, K. M. Rexrode, G. C. Curhan, E. B. Rimm, W. C. Willett, and C. S. Fuchs
Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Circulation,
March 28, 2006;
113(12):
1578 - 1587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Lu, H. B. Cottam, M. Corr, and D. A. Carson
Repression of {beta}-catenin function in malignant cells by nonsteroidal antiinflammatory drugs
PNAS,
December 20, 2005;
102(51):
18567 - 18571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Capone, M. G. Sciulli, S. Tacconelli, M. Grana, E. Ricciotti, G. Renda, P. Di Gregorio, G. Merciaro, and P. Patrignani
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects
J. Am. Coll. Cardiol.,
April 19, 2005;
45(8):
1295 - 1301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Steinhubl
The use of anti-inflammatory analgesics in the patient with cardiovascular disease: What a pain
J. Am. Coll. Cardiol.,
April 19, 2005;
45(8):
1302 - 1303.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Bresalier, R. S. Sandler, H. Quan, J. A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Riddell, D. Morton, A. Lanas, et al.
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
N. Engl. J. Med.,
March 17, 2005;
352(11):
1092 - 1102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rabausch, E. Bretschneider, M. Sarbia, J. Meyer-Kirchrath, P. Censarek, R. Pape, J. W. Fischer, K. Schror, and A.-A. Weber
Regulation of Thrombomodulin Expression in Human Vascular Smooth Muscle Cells by COX-2-Derived Prostaglandins
Circ. Res.,
January 7, 2005;
96(1):
e1 - e6.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
